U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2020
742
Substance Class Protein
Created
by admin
on Sat Dec 16 17:16:30 GMT 2023
Edited
by admin
on Sat Dec 16 17:16:30 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
9K8GNJ2874
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
NAXITAMAB
USAN   INN  
Official Name English
HUMANIZED 3F8
Common Name English
ANTI-GD2 MONOCLONAL ANTIBODY 3F8 HUMANIZED
Common Name English
NAXITAMAB [USAN]
Common Name English
HUMANIZED MONOCLONAL ANTIBODY HU3F8-IGG1
Common Name English
MONOCLONAL ANTIBODY HU3F8
Common Name English
naxitamab [INN]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMANIZED MUS MUSCULUS CLONE HU3F8 .GAMMA.1-CHAIN), DISULFIDE WITH HUMANIZED MUS MUSCULUS CLONE HU3F8 LIGHT-CHAIN, DIMER
Systematic Name English
HU3F8
Code English
ANTI-GD2 IGG3 MONOCLONAL ANTIBODY 3F8 HUMANIZED
Common Name English
Naxitamab [WHO-DD]
Common Name English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS BETA-1,4 N-ACETYLGALACTOSAMINYLTRANSFERASE 1 ((N-ACETYLNEURAMINYL)-GALACTOSYLGLUCOSYLCERAMIDE, GM2/GD2 SYNTHASE))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-449) (MUS MUSCULUS VH (IGHV2-9*02 (79%
Systematic Name English
HUMANIZED ANTI-GD2 MONOCLONAL ANTIBODY 3F8
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 416313
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
EU-Orphan Drug EU/3/18/2094
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
FDA ORPHAN DRUG 399613
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
Code System Code Type Description
CAS
1879925-92-4
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
PRIMARY
INN
10918
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
PRIMARY
DAILYMED
9K8GNJ2874
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
PRIMARY
EVMPD
SUB192785
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
PRIMARY
RXCUI
2474039
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
PRIMARY
NCI_THESAURUS
C123428
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
PRIMARY
FDA UNII
9K8GNJ2874
Created by admin on Sat Dec 16 17:16:30 GMT 2023 , Edited by admin on Sat Dec 16 17:16:30 GMT 2023
PRIMARY
From To
1_231 2_231
1_228 2_228
2_222 4_211
1_222 3_211
4_131 4_191
4_23 4_88
3_131 3_191
3_23 3_88
2_369 2_427
2_263 2_323
2_146 2_202
2_22 2_95
1_369 1_427
1_263 1_323
1_146 1_202
1_22 1_95
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_299
N 2_299
Related Record Type Details
NAXITAMAB-GQGK
SUB_CONCEPT->SUBSTANCE
NAXITAMAB I-124
LABELED -> NON-LABELED
Related Record Type Details
NAXITAMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:ESTIMATED CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966